More than 45 organizations, including the AHA, today encouraged members of the Senate Judiciary Committee to support the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974), which the panel is expected to consider next week. The legislation would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. “It is a highly-targeted remedy that will end the anticompetitive abuses utilized by some brand-name manufacturers, help restore the balance between innovation and affordability that Congress intended, and achieve the goal of more affordable prescription drugs,” the organizations said in a letter to committee leaders. “The Congressional Budget Office has estimated that enacting the CREATES Act would save $3.8 billion over 10 years. We sincerely thank you and your colleagues who have supported the CREATES Act, and we encourage all members of the Committee to vote in favor of the bill.” 

Related News Articles

Headline
The Department of Health and Human Services today issued a proposed rule revising certain provisions in a 2016 final rule implementing the Affordable Care Act’…
Headline
Reps. Bradley Schneider, D-Ill., Don Bacon, R-Neb., and Abby Finkenauer, D-Iowa, yesterday introduced a House companion to AHA-supported legislation that would…
Headline
The House Budget Committee today held a hearing on the Congressional Budget Office’s recent report on key design components and considerations for policymakers…
Headline
The Department of Health and Human Services aims to release proposed rules amending the physician self-referral (Stark law) regulations and safe-harbors under…
Headline
The Department of Health and Human Services Office for Civil Rights today published in the Federal Register its final rule concerning federal health care-…
Blog
Last week, researchers at RAND released a study that made broad claims about the prices that private insurers pay hospitals. The RAND authors relied on…